Current perspectives and concerns in corneal neurotization
- PMID: 39331430
- PMCID: PMC11573042
- DOI: 10.4103/IJO.IJO_195_24
Current perspectives and concerns in corneal neurotization
Abstract
This study aimed to comprehensively explore the intricacies of corneal neurotization (CN) and the nuanced factors that set it apart from routine clinical practice, exerting a substantial influence on its success. A symbiotic relationship is evident between corneal innervation and ocular surface health. The loss of corneal innervation results in a potentially challenging corneal condition known as neurotrophic keratopathy (NK). The majority of treatments are primarily focused on preventing epithelial breakdown rather than addressing the underlying pathogenesis. Consequently, to address the impaired corneal sensation (underlying etiology), a novel surgical approach has emerged, namely CN, which involves transferring healthy sensory nerve axons to the affected cornea. This review offers valuable insights into the existing body of supporting evidence for CN, meticulously examining clinical studies, case reports, and experimental findings. The aim is to enhance our understanding of the effectiveness and potential outcomes associated with this innovative surgical technique. The exploration of innovative therapeutic avenues holds promise for revolutionizing the management of NK, offering a potentially permanent solution to a condition once deemed incurable and severely debilitating.
Copyright © 2024 Copyright: © 2024 Indian Journal of Ophthalmology.
Conflict of interest statement
There are no conflicts of interest.
Figures
References
-
- Dua HS, Said DG, Messmer EM, Rolando M, Benitez-Del-Castillo JM, Hossain PN, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107–31. - PubMed
-
- Liu S, Pavan-Langston D, Colby KA. Pediatric herpes simplex of the anterior segment: Characteristics, treatment, and out- comes. Ophthalmology. 2012;119:2003–8. - PubMed
-
- Rosenberg ML. Congenital trigeminal anaesthesia: A review and classification. Brain. 1984;107:1073–82. - PubMed
-
- US Food and Drug Administration FDA approves first drug for neurotrophic keratitis, a rare eye disease. 2018 August 22; Accessed March 13, 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-d... .
-
- Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125:1332–43. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical